We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Collaborative Agreement Focuses on Development of Small-Molecule Therapeutics for Leukemia and Other Cancers

By LabMedica International staff writers
Posted on 28 Mar 2016
Print article
A collaborative agreement between a renowned American university-based research institute and one of the largest pharmaceutical companies in the world will focus on the development of small-molecule therapeutics for leukemia and other cancers.

Harvard University (Cambridge, MA, USA) has entered into an exclusive license and research collaboration agreement with Merck (Kenilworth, NJ, USA) to exploit novel compounds that had been developed in research laboratories at Harvard. These compounds offer an innovative approach to cancer treatment, targeting enzymes that regulate transcription.

Merck will be responsible for development of the candidate therapeutics and will engage in a research collaboration Harvard to further investigate the biology of transcriptional regulator enzymes.

Under the terms of the license agreement, Merck will pay Harvard an up-front fee of 20 million USD and will be responsible for development, including clinical development, and for worldwide commercialization of products. Harvard University will also be eligible to receive development and commercialization milestone payments, as well as tiered royalties on any resulting products.

“Accelerator funding over the course of several years has enabled my laboratory to advance some of our experimental compounds to a relatively late stage of preclinical development,” said Dr. Matthew Shair, professor of chemistry and chemical biology at Harvard University. “It is gratifying to have discovered a new biological target in the fight against acute myeloid leukemia (AML), but even more fulfilling to have created a promising weapon against it.”

“This recent agreement with the Shair laboratory is rooted in our belief that collaboration is the cornerstone for improving cancer care and driving innovation. It is the partnership among industry and academia that is truly critical to transforming cancer treatment and advancing the care for patients with difficult-to-treat blood cancers, such as acute myeloid leukemia,” said Dr. Eric Rubin, vice president and therapeutic area head, oncology early stage development at Merck Research Laboratories.

“University researchers bring a great degree of creativity and innovation to the toughest challenges in human medicine,” said Isaac T. Kohlberg, senior associate provost and chief technology development officer at Harvard University. “Professor Shair’s inventive leukemia research has reached a stage of development that is unusual in most universities but of great interest to the health care industry and ultimately to patients. His work could change the way clinicians treat a major disease.”

Related Links:

Harvard University 
Merck


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.